{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:50:59Z","timestamp":1770457859260,"version":"3.49.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clml.2021.09.021","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T09:48:11Z","timestamp":1633772891000},"page":"236-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazia","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Skikne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CL","family":"Beach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.09.021_bib0001","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.021_bib0002","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.021_bib0003","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2018.00041","article-title":"Epigenetic regulators in the development, maintenance, and therapeutic targeting of acute myeloid leukemia","volume":"8","author":"Sun","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0005","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.021_bib0006","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2021.09.021_bib0007","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood-2009-01-200519","article-title":"MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation","volume":"114","author":"Figueroa","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","article-title":"Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia","volume":"127","author":"Wouters","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0009","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.09.021_bib0010","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-08-1247","article-title":"Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers","volume":"14","author":"Braiteh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.09.021_bib0011","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines: acute myeloid leukemia, version 3.2020."},{"key":"10.1016\/j.clml.2021.09.021_bib0012","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. myelodysplastic syndromes version 2.2020."},{"key":"10.1016\/j.clml.2021.09.021_bib0013","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0014","series-title":"Vidaza\u00ae (azacitidine) Prescribing Information","year":"2018"},{"key":"10.1016\/j.clml.2021.09.021_bib0015","unstructured":"Dacogen\u00ae (decitabine) Prescribing Information. Otsuka America Pharmaceuticals Inc, Rockville, MD; Revision 12\/2018., 2018."},{"key":"10.1016\/j.clml.2021.09.021_bib0016","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0017","unstructured":"European Medicines Agency. Vidaza (azacitidine). 2016: EMA\/450923\/452016."},{"key":"10.1016\/j.clml.2021.09.021_bib0018","unstructured":"European Medicines Agency. Dacogen (decitabine). 2012: EMA\/461407\/462012."},{"key":"10.1016\/j.clml.2021.09.021_bib0019","unstructured":"INQOVI\u00ae (decitabine and cedazuridine) tablets prescribing information. Astex Pharmaceuticals, Inc., Pleasanton, CA. Rev 07\/20."},{"key":"10.1016\/j.clml.2021.09.021_bib0020","unstructured":"ONUREG\u00ae (azacitidine tablets) prescribing information. Celgene Corporation (a wholly owned subsidiary of Bristol-Myers Squibb), Summit, NJ. Rev 09\/20."},{"key":"10.1016\/j.clml.2021.09.021_bib0021","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0022","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2021.09.021_bib0023","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.20.02619","article-title":"Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"39","author":"Garcia-Manero","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0024","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1634\/theoncologist.2015-0165","article-title":"Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"20","author":"Cogle","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.09.021_bib0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.09.021_bib0026","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","article-title":"Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy","volume":"19","author":"Mahfouz","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.09.021_bib0027","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","article-title":"Clinical update on hypomethylating agents","volume":"110","author":"Duchmann","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2021.09.021_bib0028","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2021.09.021_bib0029","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1097-0185(199801)250:1<6::AID-AR2>3.0.CO;2-4","article-title":"Changes in the rate of RNA synthesis during the cell cycle","volume":"250","author":"Salem","year":"1998","journal-title":"Anat Rec"},{"key":"10.1016\/j.clml.2021.09.021_bib0030","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.09.021_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2021.09.021_bib0032","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1039\/C1MD00194A","article-title":"Small molecules DNAmethyltransferasesinhibitors","volume":"3","author":"Martinet","year":"2012","journal-title":"MedChemComm."},{"key":"10.1016\/j.clml.2021.09.021_bib0033","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/1535-7163.MCT-08-0411","article-title":"Azacytidine causes complex DNA methylation responses in myeloid leukemia","volume":"7","author":"Stresemann","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2021.09.021_bib0034","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.1813666116","article-title":"Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome","volume":"116","author":"Leung","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2021.09.021_bib0035","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/leu.2008.397","article-title":"The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells","volume":"23","author":"Flotho","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.09.021_bib0036","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","article-title":"Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes","volume":"20","author":"Unnikrishnan","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2021.09.021_bib0037","doi-asserted-by":"crossref","first-page":"28812","DOI":"10.18632\/oncotarget.15807","article-title":"Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive\/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease","volume":"8","author":"Tobiasson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.09.021_bib0038","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clml.2021.09.021_bib0039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-137606","article-title":"CC-486 mechanism imparted by extended exposure of azacitidine upregulates myeloid differentiation markers and induces cell death in AML cells","volume":"136","author":"Dunshee","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/DDDT.S3143","article-title":"Safety and efficacy of azacitidine in myelodysplastic syndromes","volume":"4","author":"Vigil","year":"2010","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.clml.2021.09.021_bib0041","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/1097-0142(19810401)47:7<1739::AID-CNCR2820470702>3.0.CO;2-2","article-title":"Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study","volume":"47","author":"Saiki","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.09.021_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135520","article-title":"Pharmacokinetics and pharmacodynamics with extended dosing of CC-486 in patients with hematologic malignancies","volume":"10","author":"Laille","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2021.09.021_bib0043","first-page":"2770","article-title":"Phase specificity of 5-azacytidine against mammalian cells in tissue culture","volume":"30","author":"Li","year":"1970","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2021.09.021_bib0044","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fphar.2018.01380","article-title":"Biomodulatory treatment with azacitidine, all-trans retinoic acid and pioglitazone induces differentiation of primary AML blasts into neutrophil like cells capable of ROS production and phagocytosis","volume":"9","author":"Klobuch","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2021.09.021_bib0045","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2015.265","article-title":"Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Garcia-Manero","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.09.021_bib0046","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/asheducation-2013.1.511","article-title":"Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes","volume":"2013","author":"Saunthararajah","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.09.021_bib0047","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0048","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/leu.2008.145","article-title":"A pilot pharmacokinetic study of oral azacitidine","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.09.021_bib0049","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/phar.1371","article-title":"A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment","volume":"34","author":"Laille","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clml.2021.09.021_bib0050","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jcph.251","article-title":"Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies","volume":"54","author":"Laille","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clml.2021.09.021_bib0051","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00280-020-04037-9","article-title":"Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer","volume":"85","author":"Babiker","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2021.09.021_bib0052","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0053","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ajh.25216","article-title":"Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies","volume":"93","author":"Savona","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.09.021_bib0054","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.09.021_bib0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.leukres.2018.08.001","article-title":"CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia","volume":"72","author":"Garcia-Manero","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.09.021_bib0056","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0057","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0058","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2010.01456.x","article-title":"Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine","volume":"85","author":"Santini","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.09.021_bib0060","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0061","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0062","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.09.021_bib0063","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.beha.2009.10.004","article-title":"Optimising the conditioning regimen for acute myeloid leukaemia","volume":"22","author":"Appelbaum","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2021.09.021_bib0064","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.021_bib0065","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.09.021_bib0066","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.09.021_bib0067","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2021.09.021_bib0068","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020224","article-title":"Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia","volume":"11","author":"Ferrara","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2021.09.021_bib0069","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.1991.tb01560.x","article-title":"Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia","volume":"47","author":"Palva","year":"1991","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.09.021_bib0070","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0071","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/leu.2012.153","article-title":"A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission","volume":"26","author":"Boumber","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.09.021_bib0072","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/blood-2011-02-337725","article-title":"Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia","volume":"117","author":"Buyse","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0073","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0074","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2005-10-4073","article-title":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","volume":"108","author":"Brune","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2016.252","article-title":"Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)","volume":"31","author":"Blum","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.09.021_bib0076","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.1998.16.3.872","volume":"16","author":"Lowenberg","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0077","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3346\/jkms.2015.30.10.1416","article-title":"Oral maintenance chemotherapy with 6-mercaptopurine and methotrexate in patients with acute myeloid leukemia ineligible for transplantation","volume":"30","author":"Choi","year":"2015","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.clml.2021.09.021_bib0078","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2016.67.6213","article-title":"Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study","volume":"35","author":"Pigneux","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0079","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/fon.15.326","article-title":"Design of the randomized, phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia","volume":"12","author":"Roboz","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0080","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","article-title":"General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale","volume":"21","author":"Montan","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2021.09.021_bib0081","series-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","article-title":"Self-reported population health: an international perspective based on EQ-5D","author":"Szende","year":"2014"},{"key":"10.1016\/j.clml.2021.09.021_bib0082","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clml.2021.09.021_bib0083","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/JCO.2020.38.15_suppl.7533","article-title":"Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC)","volume":"38","author":"Roboz","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0084","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-140837","article-title":"CC-486 prolongs survival for patients with Acute Myeloid Leukemia (AML) in remission after Intensive Chemotherapy (IC) independent of the presence of Measurable Residual Disease (MRD) at study entry: results from the QUAZAR AML-001 maintenance trial","volume":"136","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0085","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2020.38.15_suppl.7513","article-title":"Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: results from the phase III QUAZAR AML-001 maintenance trial","volume":"38","author":"Dohner","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0086","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12878-016-0049-5","volume":"16","author":"Garcia-Manero","year":"2016","journal-title":"BMC Hematol"},{"key":"10.1016\/j.clml.2021.09.021_bib0087","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0088","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.09.021_bib0089","article-title":"A phase III placebo-controlled trial of CC-486 in patients with red blood cell transfusion-dependent (RBC-TD) anemia and thrombocytopenia due to IPSS lower-risk myelodysplastic syndromes (LR-MDS)","volume":"4","author":"Garcia-Manero","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2021.09.021_bib0090","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-132405","article-title":"The QUAZAR AML maintenance trial: results of an international phase III, randomized, double-blind, placebo-controlled study of CC-486 (Oral Formulation of Azacitidine) in patients with acute myeloid leukemia (AML) in first remission","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0091","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S2152-2650(20)30726-6","article-title":"Gastrointestinal events and management strategies for patients with Acute Myeloid Leukemia(AML) in first remission receiving CC-486 maintenance therapy in the randomized, placebo-controlled, phase III QUAZAR AML-001 trial","volume":"20","author":"Ravandi","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.09.021_bib0092","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.7530","article-title":"CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (\u226575 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: results from the phase III QUAZAR AML-001 trial","volume":"38","author":"Ravandi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0093","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0094","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2021.09.021_bib0095","first-page":"679","article-title":"Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics","volume":"6","author":"Witticke","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2021.09.021_bib0096","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-137562","article-title":"CC-486 reduces hospitalization and associated estimated costs in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy: results from the QUAZAR AML-001 maintenance trial","volume":"136","author":"Oliva","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0097","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11523-020-00709-x","article-title":"Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model","volume":"15","author":"Ramsey","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2021.09.021_bib0098","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0099","article-title":"Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine","volume":"134","author":"Savona","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-133855","article-title":"Clinical efficacy and safety of oral decitabine\/cedazuridine in 133 patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)","volume":"136","author":"Savona","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0101","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25620","article-title":"Maintenance therapy in AML: the past, the present and the future","volume":"94","author":"Molica","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.09.021_bib0102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0103","volume":"134","author":"D\u00f6hner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0104","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.clml.2019.07.090","article-title":"Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)","volume":"19","author":"DiNardo","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.09.021_bib0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110976","volume":"132","author":"Esteve","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.021_bib0106","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.09.021_bib0107","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1080\/10428194.2019.1571201","article-title":"Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)","volume":"60","author":"Kalff","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.09.021_bib0108","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.09.021_bib0109","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/1078-0432.CCR-17-3716","article-title":"Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors","volume":"24","author":"Von Hoff","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.09.021_bib0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2019.10.002","article-title":"Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma","volume":"123","author":"Mesia","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2021.09.021_bib0111","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2018.11.028","article-title":"Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer","volume":"108","author":"Levy","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2021.09.021_bib0112","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1002\/cncr.31779","article-title":"ABOUND.2L+: a randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)","volume":"124","author":"Morgensztern","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.09.021_bib0113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12964-017-0168-z","article-title":"The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation","volume":"15","author":"Wolff","year":"2017","journal-title":"Cell Commun Signal"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502102070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502102070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:55Z","timestamp":1761871135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502102070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S215226502102070X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}